Last reviewed · How we verify
Omegaven Therapy
At a glance
| Generic name | Omegaven Therapy |
|---|---|
| Sponsor | Amarnath, Rathna, M.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
- Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury (PHASE2)
- Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |